{"result": "(\"entity\"<|>VLDL<|>ORGANIZATION<|>VLDL refers to Very Low-Density Lipoprotein, a type of lipoprotein responsible for transporting triglycerides in the blood.)\n##\n(\"entity\"<|>IRC<|>EVENT<|>IRC stands for Insuficiencia Renal Crónica, which translates to Chronic Kidney Disease, a medical condition affecting kidney function.)\n##\n(\"entity\"<|>FRCV<|>EVENT<|>FRCV stands for Factor de Riesgo Cardiovascular, which translates to Cardiovascular Risk Factor, indicating various health risks associated with cardiovascular diseases.)\n##\n(\"entity\"<|>HMG-CoA REDUCTASE<|>ORGANIZATION<|>HMG-CoA Reductase is an enzyme that plays a central role in the production of cholesterol in the liver.)\n##\n(\"entity\"<|>ESTATINAS<|>ORGANIZATION<|>Estatinas, or statins, are a class of drugs used to lower cholesterol levels in the blood and reduce cardiovascular risk.)\n##\n(\"entity\"<|>FIBRATOS<|>ORGANIZATION<|>Fibratos, or fibrates, are medications used to lower triglyceride levels and increase HDL cholesterol.)\n##\n(\"entity\"<|>ÁCIDO NICOTÍNICO<|>ORGANIZATION<|>Ácido nicotínico, or niacin, is a vitamin used in the treatment of dyslipidemia, helping to lower cholesterol levels.)\n##\n(\"entity\"<|>HIPERTRIGLICERIDEMIA<|>EVENT<|>Hipertrigliceridemia refers to high levels of triglycerides in the blood, a condition that can increase the risk of cardiovascular disease.)\n##\n(\"relationship\"<|>VLDL<|>ESTATINAS<|>Estatinas are used to lower the levels of VLDL in the blood, thereby reducing cardiovascular risk.<|>8)\n##\n(\"relationship\"<|>IRC<|>FRCV<|>IRC is a significant factor contributing to FRCV, as chronic kidney disease increases cardiovascular risk.<|>7)\n##\n(\"relationship\"<|>HMG-CoA REDUCTASE<|>ESTATINAS<|>Estatinas inhibit HMG-CoA Reductase, which is crucial for cholesterol biosynthesis.<|>9)\n##\n(\"relationship\"<|>FIBRATOS<|>HIPERTRIGLICERIDEMIA<|>Fibratos are used to treat hipertrigliceridemia by lowering triglyceride levels in the blood.<|>8)\n##\n(\"relationship\"<|>ÁCIDO NICOTÍNICO<|>ESTATINAS<|>Ácido nicotínico is often used in conjunction with estatinas to enhance lipid-lowering effects.<|>6)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: VLDL\n                            • Diabetes o IRC en estadio 3-4 sin otros                                                                                elevado.\n                              FRCV\n       Riesgo               • Dos o menos FRCV y riesgo CV a 10                                                                                  D.  Fármacos metabolizados por el citocromo P450, como el ketoconazol, aumentan\n       moderado               años < 10%                                          <100            <130             <90                               los niveles plasmáticos de estatinas y el riesgo de miopatía.\n       Riesgo bajo          • 0 FRCV                                              <130            <160             NR\n     CV: cardiovascular; ECV: enfermedad cardiovascular; FRCV: factor de riesgo cardiovascular; HFH: hipercolesterolemia familiar heteroci-      COMENTARIO\n     gota; IRC: insuficiencia renal crónica; SCA: síndrome coronario agudo..                                                                     Las estatinas son los fármacos más ampliamente utilizados para el tratamiento de los\n     El ácido nicotínico se ha usado en el tratamiento de la dislipidemia desde hace más de                                                      pacientes con dislipidemia y de los que hay una mayor evidencia de beneficios en la mor-\n     40 años. Su principal mecanismo de acción es la disminución de la producción y liberación                                                   bimortalidad cardiovascular. Su mecanismo de acción es la inhibición competitiva de la\n     de las VLDL; asimismo, también disminuye la liberación de ácidos grasos libres del tejido                                                   3-hidroxi-3-metilglutaril-coenzima           A  (HMG-CoA)       reductasa,      bloqueando      la conversión       de\n     adiposo a la circulación. Los efectos en los lípidos plasmáticos se cifran en una reducción                                                 la HMG-CoA en mevalonato, un paso precoz en la biosíntesis del colesterol a nivel hepáti-\n     del 5-20% en el colesterol LDL, un aumento del colesterol HDL del 15-25% y un descenso de                                                   co. Así, al disminuir la concentración intracelular de colesterol, incrementan el número de\n     los triglicéridos del 20-40%. Asimismo, es uno de los pocos agentes que también disminuye                                                   receptores de LDL a nivel del hepatocito, lo que aumenta la depuración del LDL plasmático y\n     la lipoproteína A.                                                                                                                          de otras partículas aterogénicas que contienen apo B. Se recomienda administrarlos por la\n                                                                                                                                                 noche, ya que es cuando la actividad de la HMG-CoA reductasa es más alta, y su eficacia hipo-\n     Los   fibratos son ampliamente utilizados en el tratamiento de la hipertrigliceridemia. Ac-                                                 colesterolemiante es ampliamente reconocida, con unos efectos dosis-dependientes y dife-\n     túan como agonistas del receptor α activado por el proliferador de peroxisomas (PPAR-α),                                                    rentes, según el tipo de estatina usada, que pueden ser un descenso del colesterol LDL del\n     regulando varios pasos del metabolismo lipídico. En los estudios, el uso de fibratos se ha                                                  18-55%,    un descenso de los triglicéridos de un 7-30% y un aumento                          del colesterol HDL\n     asociado a una reducción marcada de los triglicéridos (20-50%) y a un incremento mode-                                                      del 5-15%.\n     rado del colesterol HDL (5-35%). El descenso del colesterol LDL es variable y puede llegar                                                  Se ha comprobado que doblar la dosis de cualquier estatina produce una reducción adi-\n     a ser del 5-20% (más con fenofibrato que con gemfibrozilo), pero en algunos casos, sobre                                                    cional del colesterol de un 6%, lo que se ha denominado “la regla del 6”. Así, el incremento\n     todo en hipertrigliceridemias graves, pueden llegar a incrementar algo sus cifras. También                                                  de una dosis inicial de atorvastatina de 10 mg a una dosis de 80 mg solo producirá una\n     incrementan el tamaño de las lipopartículas de LDL.                                                                                         reducción adicional del colesterol del 18% (aumento de 10 a 20, de 20 a 40 y de 40 a 80 mg,\n\n\n\n462                                                                                                                                                                                                                                                                        463\n---\n                                                                                                                                                                                                                  OBESIDAD,               LÍPIDOS                      8\n                                                                                                                                                                                     Y TRASTORNOS ELECTROLÍTICOS\n\n\n\n         con un 6% de reducción del colesterol con cada incremento de la dosis). Obviamente, este                                               COMENTARIO\n         fenómeno reduce la eficacia del incremento de la dosis de estatinas en la consecución de                                               Se presentan niveles elevados de triglicéridos en ayunas y, dado que existe menor certidumbre\n         los objetivos terapéuticos necesarios en cada caso, y muy especialmente en los pacientes                                               respecto a la relación existente entre los triglicé\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}